On June 17, 2025, AIM ImmunoTech Inc. received a warning from NYSE American for not meeting the required stockholders’ equity of $4 million, reporting a deficit of $3.9 million and continuous losses over the past five years. The company has until June 11, 2026, to regain compliance, and the warning won't affect its trading on the exchange.